Integra LifeSciences / Codman Neurosurgery Business merger inquiry

The CMA investigated and cleared the anticipated acquisition by Integra LifeSciences Holdings Corporation of the Codman Neurosurgery Business.

• From: Competition and Markets Authority
• Published: 26 May 2017
• Last updated: 3 August 2017 — See all updates

• Case type: Mergers
• Case state: Closed
• Market sector: Healthcare and medical equipment
• Outcome: Mergers - phase 1 clearance
• Opened: 26 May 2017
• Closed: 3 August 2017

Statutory timetable

Phase 1 date	Action
3 August 2017	Decision published
6 July 2017	Decision announced
26 May to 12 June 2017	Invitation to comment
26 May 2017	Launch of merger inquiry

Phase 1

CMA clearance decision

6 July 2017: The CMA has cleared the anticipated acquisition by Integra LifeSciences Holdings Corporation of the Codman Neurosurgery Business, using the ‘de minimis’ exception. The full text of the decision is available below.

• Full text decision (3.8.17)

Invitation to comment: Now closed

26 May 2017: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Launch of merger inquiry

26 May 2017: The CMA announced the launch of its merger inquiry by notice to the parties.

• Commencement of initial period of notice (26.5.17)

Contact

Please send written representations about any competition or public interest to:

mergersupportteam@cma.gsi.gov.uk

Published 26 May 2017
Last updated 3 August 2017 + show all updates

1. 3 August 2017

   Full text of the decision published.

2. 6 July 2017

   Clearance decision announced.

3. 26 May 2017

   First published.